MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Akciju saraksts・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Atvērts

4.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.71

Max

4.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-10M -7.7M
Pārdošana	-10M 529K
Peļņas marža	-1,463.516
Darbinieki	44
EBITDA	-10M -7.7M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 26. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	28M 908M
Iepriekšējā atvēršanas cena	4.77
Iepriekšējā slēgšanas cena	4.77

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

3.255 / 3.365 Atbalsts un pretestība

Arbutus Biopharma Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. janv. 22:45 UTC

Galvenie tirgus virzītāji

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026. g. 4. janv. 23:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

2026. g. 4. janv. 23:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

2026. g. 4. janv. 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. janv. 23:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

2026. g. 4. janv. 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

2026. g. 4. janv. 23:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 4. janv. 23:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

2026. g. 4. janv. 23:17 UTC

Galvenie ziņu notikumi

Spot Gold Rises 0.8% to $4,365.24/oz

2026. g. 4. janv. 23:16 UTC

Galvenie ziņu notikumi

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

2026. g. 4. janv. 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

2026. g. 4. janv. 23:13 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

2026. g. 4. janv. 23:12 UTC

Tirgus saruna

Galvenie ziņu notikumi

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

2026. g. 4. janv. 22:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

2026. g. 4. janv. 21:00 UTC

Peļņas

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

2026. g. 4. janv. 20:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 4. janv. 20:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

2026. g. 3. janv. 18:59 UTC

Galvenie ziņu notikumi

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

2026. g. 3. janv. 17:42 UTC

Galvenie ziņu notikumi

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

2026. g. 3. janv. 17:40 UTC

Galvenie ziņu notikumi

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

2026. g. 3. janv. 16:10 UTC

Galvenie ziņu notikumi

What Maduro's Capture Means for Chevron Stock -- Barrons.com

2026. g. 3. janv. 15:53 UTC

Galvenie ziņu notikumi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026. g. 3. janv. 15:03 UTC

Galvenie ziņu notikumi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026. g. 3. janv. 14:10 UTC

Galvenie ziņu notikumi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

2026. g. 3. janv. 12:16 UTC

Galvenie ziņu notikumi

U.S. Captures Maduro, Trump Says -- Barrons.com

2026. g. 3. janv. 09:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. janv. 09:20 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 3. janv. 00:43 UTC

Iegādes, apvienošanās, pārņemšana

Research Reports -- Barrons.com

2026. g. 2. janv. 22:13 UTC

Tirgus saruna

Peļņas

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Arbutus Biopharma Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arbutus Biopharma Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.255 / 3.365Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.